BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-
CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially …

Understanding the risks of COVID-19 in patients with Multiple Sclerosis (MS) receiving
disease-modifying therapies (DMTs) and their immune reactions is vital to analyze vaccine …

Background Vaccination campaign to contrast the spread of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has raised the issue of vaccine immunogenicity in …

Abstract Background Sphingosine-1-phosphate receptor (S1P) modulators and anti-CD20
therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies …

Background and Aims: The National Multiple Sclerosis Society and other expert
organizations recommended that all patients with multiple sclerosis (MS) should be …

Abstract The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions
regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have …

Background Immunomodulatory/immunosuppressive activity of multiple sclerosis (MS)
disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 …

Abstract Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target
immunity and have the potential to increase the risk of severe acute respiratory syndrome …

Abstract Background In patients with Multiple Sclerosis (pwMS) disease-modifying therapies
(DMTs) affects immune response to antigens. Therefore, post-vaccination serological …

Background COVID-19 vaccination is recommended for patients with multiple sclerosis
(pwMS), while disease-modifying therapies (DMTs) may influence the efficacy of SARS-CoV …